Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some signaling pathways are well defined in HS, the role of TNF-like ligand 1 (TL1A) is not well understood. A group of researchers has investigated the association of TL1A with HS, as well as its association with other cytokine networks.
Vidac Pharma Holding plc has announced the initiation of an in vivo preclinical program to evaluate the potential of its hexokinase 2 (HK2)/voltage-dependent anion channel (VDAC)-targeting approach in psoriasis.
Almirall SA has submitted a CTA filing for a bispecific antibody targeting IL-13 and OX-40L for the treatment of atopic dermatitis. The company expects to initiate a first-in-human phase I trial during the first half of this year.
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in disease activity, thus there is a need for novel medications.
Hidradenitis suppurativa (HS) is a chronic autoinflammatory condition affecting the skin, the genetic mechanisms of which are not well understood. A group of researchers set out to explore the genetic background of familial HS by performing whole-exome sequencing on genomic DNA from patients.
Atopia Therapeutics SA has reported new preclinical in vivo efficacy data supporting the potential of ATP-R13 as a novel oral treatment for atopic dermatitis.
Enanta Pharmaceuticals Inc. has announced a new immunology program and updated progress in its immunology pipeline. The company’s new program is focused on developing oral MRGPRX2 inhibitors for type 2 immune driven diseases, with an initial focus on chronic spontaneous urticaria and other mast cell-driven diseases.
Jiangsu Simcere Pharmaceutical Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising antibody or antigen-binding fragments linked to a cytotoxic drug through a linker reported to be useful for the treatment of atopic dermatitis.
Fibrobiologics Inc. has filed an IND application with the FDA seeking to begin first-in-human trials of CYPS-317, an investigational allogeneic fibroblast spheroid-based therapy for the treatment of moderate to severe psoriasis.
RSS
